AstraZeneca
Recent developments from AstraZeneca summarized
Published in Healthcare Mergers, Acquisitions and Ventures Week, January 20th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at AstraZeneca.
Report 1: AstraZeneca announced its intention to expand the development plan for CytoFab, a treatment for severe sepsis, with the addition of a 480-patient phase II study program.
The company has recently completed consultations with regulators in the U.S. and E.U. These consultations confirmed that a single phase III study could be sufficient for regulatory approval. Furthermore, to meet the regulatory needs of both agencies, it is required that AstraZeneca implement a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- Adverse Drug Reaction
Bayer informs healthcare professionals of safety revisions to the Trasylol label - Adverse Drug Reactions
Elan Pharmaceuticals, Inc. describes research in adverse drug reactions - Adverse Drug Reactions
New adverse drug reactions data have been reported by scientists at GlaxoSmithKline - Alzheimer Disease
Dosing commenced in Phase IIa trial of PBT2 in early Alzheimer patients - Anemia
Roche submits added data to U.S. FDA to support license application for anti-anemia agent - Angiogenesis
Findings from Genentech, Inc. provide new insights into angiogenesis - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
